An analysis of longitudinal data with up to 25 years of follow-up has identified five disease categories for which clozapine use was associated with higher risk of adverse drug events. The Finnish study found higher-than-expected prevalence of ileus and pneumonia in patients receiving clozapine, with both illnesses associated with greater mortality.
Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open-label trial has found. The vast majority of patients in the study's switch group stopped taking a first-generation antipsychotic and continued on their second-generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research.
Women of menopausal age with schizophrenia or schizoaffective disorder who used menopausal hormone therapy experienced a reduced risk of psychotic relapse compared with non-use, a study using a within-individual design has found. Relapse risk was decreased in women who initiated hormone therapy between the ages of 40 and 55.
A few years ago, I found myself evaluating a clinic patient whose chief complaint was poor concentration, which he maintained was so severe that he could not even hold down a menial job. Fortunately, he was happy to provide me with his diagnosis (“ADHD”) and knew exactly which medication would eliminate his symptoms: amphetamine (I'm using the term broadly here to encompass the numerous pharmaceutical preparations of this drug that are currently available).
A case-control study involving patients with a psychiatric hospitalization has found increased odds of psychosis and mania in individuals with past-month use of prescription amphetamines. Risk of psychosis and mania was substantially higher in patients receiving higher doses of amphetamines, the investigators reported. Study results were published online Sept. 12, 2024, in the American Journal of Psychiatry.
Divalproex sodium, valproic acid, valproate (generic) — Depakote, Depakene (brand)
The atypical antipsychotic clozapine is considered the primary agent for patients with treatment-resistant schizophrenia, and is also used at times in the treatment of other treatment-resistant psychotic disorders. Despite its efficacy, use of clozapine is often limited by the occurrence of significant adverse effects, smoking-induced increased metabolism, and drug-drug interactions due to co-administered medications to treat concurrent medical and psychiatric conditions.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：